Cancer Stem Cell & Oncology Research

Stewart Sell completed his graduation from University of Pittsburg. He was appointed as associate professor at University of California and became professor of pathology at University of Texas in the year 1997. In 2003 he became professor of pathology at University of Albany.

Cancer, carcinogenesis, and aging

Dr. Jimmy Efird is an Associate Member of the Leo Jenkins Cancer at Brody School of Medicine. Additionally, he holds a joint appointment as Associate Professor in the Department of Public Health and as Epidemiologist/Chief Statistician (Director, Shared Resources) in the Center for Health Disparities. Dr. Efird received his Ph.D. from Stanford University (Epidemiology with a concentration in Biostatistics). His expertise includes statistical methods for assessing geneenvironment interaction, clinical trial design, computing power and sample size for correlated samples, and multiplicity adjustment for confidence intervals. He has over 100 publications in scientific journals and technical proceedings. Additionally, Dr. Efird serves as a Senior Consultant for The NCRR-funded RCMI Translational Research Network Data and Technology Coordinating Center.

Genetic epidemiology, cancer informatics, brain tumours, soft-tissue sarcomas, and HPV-related cancers.  Additionally, Bioinformatics and Genomics

Anupam Bishayee is the Chair and Associate Professor of Pharmaceutical Sciences, American University of Health Sciences, Signal Hill, CA. His research focuses on elucidation of the cancer preventive and therapeutic effects of medicinal plants, natural products, dietary and synthetic agents using various pre-clinical models of cancer. His ongoing projects are funded by the National Institutes of Health as well as private pharmaceutical/biotechnological institutions. He has published more than 86 original research papers and review articles in high-impact, peer-reviewed journals, 9 book chapters, and presented over 25 papers at various national and international scientific meetings.

Cancer chemoprevention and chemotherapy by dietary agents and phytochemicals, chemoprevention of hepatocarcinogenesis and hepatocellular carcinoma, chemoprevention of mammary carcinogenesis and breast cancer resveratrol and cancer chemoprevention berry and cancer chemoprevention Oxidative stress, inflammation and cancer

Shiaw-Yih Lin has studied DNA damage response in cancer for 10+ years, during which time he has authored more than 40 peer-reviewed reports. He has served on the editorial boards for the World Journal of Clinical Oncology, American Journal of Cancer Research, Frontiers in Molecular and Cellular Oncology, World Journal of Translational Medicine, and Experimental Hematology & Oncology. He is a member of the International Scientific Advisory Board for International Institute of Anticancer Research, and he has served on numerous review committees for the NIH, DOD and Susan G. Komen for the Cure.

Endrometrial Cancer
Breast Cancer Dormancy
Functional and clinical analysis of Rak in breast cancer suppression

Liang Xu is a professor in the Department of Molecular Bioscience in University od Kansas. The goal of the proposed research is to establish nanovectors as a gene/miRNA delivery platform to develop novel molecular therapies targeting cancer stem cells. In summary he has a demonstrated record of successful and productive research projects relevant to the his research field and his expertise and experience have prepared him to go for invention of a new direction in cancer research.

Molecular therapy targeting cancer and cancer stem cells, cancer biology, drug discovery and drug/gene delivery.(Funded by multiple NIH and DOD grants). Molecularly targeted cancer therapy and chemo/radiosensitization by modulating cell death signaling pathways, autophagy and apoptosis. Exploring microRNAs as novel targets for cancer and cancer stem cells. Nanovectors targeting cancer cells for siRNA/miRNA-based novel cancer therapeutics. Nanovectors targeting cancer stem cells and exploring novel molecular therapy for cancer stem cells.

Tumor cell invasion and metastasis, cancer cell metabolism, Cancer cells migrate

Tapan Bera received his M.S. and Ph.D. in Biochemistry from the Calcutta University, India. He completed his postdoctoral research training in the Cancer Research Laboratory, UC Berkeley and in the Laboratory of Molecular Biology, National Cancer Institute. Currently he held the Associate Scientist position at the National Cancer Institute, NIH, USA. His research objectives are focused mainly on to understand the molecular basis of cancer by identifying the genes involved in this process and translate that information to possible targeted therapy of cancer. He has discovered several very interesting and important genes whose expression is restricted to normal prostate and prostate cancer and are now being developed as therapeutic targets for the treatment of prostate cancer. He is author/co-author in more than 65 papers published in peer-reviewed journals.

Cancer biology and Immunotherapy

Yaguang Xi serves as an Assistant Professor of oncologic sciences at the Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA. In 2003, Dr. Xi earned his Ph.D. degree in cancer biology from the Peking University after he accomplished the medical training. His expertise covers molecular biology, cell biology, genomics, genetics, oncology, and bioinformatics. Currently, Dr. Xi focuses on characterizing micro-RNA biomarkers and validating their important roles in cancer development, tumor metastasis, chemotherapy, and prevention.

Cell biology, genomics, genetics, oncology

Reza Hakkak is Professor in the Department of Dietetics and Nutrition, University of Arkansas for Medical Sciences. He is nutritionist, Professor of Pediatrics in the College of Medicine, and Maternal Child Health in the College of Public Health.

Influence of diet and nutrition on cancer prevention, Obesity and Breast Cancer promotion, Animal modeling for Cancer Research, nutrition education, interactions of diet and drug metabolism, and alcohol as a risk factor for cancer development.

Samir A Farghaly is a Physician/Scientist, and faculty member of the Medical College of Cornell University and The New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his Ph.D. Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewers of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer, mutant BRCA1 and BRCA2 genes profiles in ovarian cancer, proteomic profiling of metastatic genes of ovarian cancer, targeted molecular therapy for advanced epithelial ovarian cancer, minimally invasive surgery for gynecological cancer

Kenji Suzuki received his Ph.D. degree in information engineering from Nagoya University in 2001. From 1993 to 2001, he worked at Hitachi Medical Corporation and then Aichi Prefectural University as faculty. In 2001, he joined Department of Radiology at University of Chicago. Since 2006, he has been Assistant Professor of Radiology, Medical Physics and Cancer Research Center there. He has published 200 papers (including 75 peer-reviewed journal papers). He has been serving as the Editor-in-Chief and an Associate Editor of 12 leading international journals including Medical Physics, International Journal of Biomedical Imaging and Academic Radiology. He has received Paul Hodges Award, three RSNA Certificate of Merit Awards and Research Trainee Prize, Cancer Research Foundation Young Investigator Award, SPIE Honorable Mention Poster Award, IEEE Outstanding Member Award and Kurt Rossmann Excellence in Teaching Award. He has been a Senior Member of IEEE since 2004.

Kenji Suzuki areas of expertise are medical image analysis and quantitative imaging.

He was graduated from Tokyo College of Pharmacy. AZer completing his graduate study, he worked on radioactive tracer in drug metabolism as a research assistant at Physical pharmacy department. AZer obtained Ph.D. degree in Pharmaceutical sciences, he joined Dr. Lester Packer’s lab as a post‐doctoral fellow at University of California, Berkeley where he engaged in membrane bioenergetics research on halobacterial rhodopsin. In 1985, he obtained professor position and established radiopharmaceu8cal science lab at Niigata College of Pharmacy where free radical biology and molecular biological researches were developed. 2001, he engaged in establishing Food Science department in NUPALS and started food func8on study using an8oxidant tradi8onal oriental medicine formula as a food model. Current topics of his research are the food func8ons modula8ng DNA damage responses and aging, especially cell cycle checkpoint kinases and their applica8on in Complementary medicine in Cancer treatment. He published more than 150 papers in peer reviewed journal. He served as reviewer, editor of several scien8fic journals and for other social events. He has been chairing Interna8onal Niigata Symposium on Diet and Health since 2004.

Food functions modulating DNA damage responses and aging, especially cell cycle checkpoint kinases and their application in Complementary medicine in Cancer treatment.

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer

cancer research, charged particle optics, early detection of cancer and delayed detection of cancer

Dr. Chen is an Associate Professor at the Beckman Research Institute, City of Hope. Dr. Chen received his Ph.D. in Molecular Biology at the University of Alabama at Birmingham in 1999, and completed his postdoctoral training in Cancer Biology at Johns Hopkins University in 2005. Dr. Chen’s research covers epigenetic mechanisms of tumorigenesis, gene regulation by DNA methylation and histone modifications, animal models of cancer, and stem cells. Dr. Chen’s current research is on functions of sirtuin deacetylases in aging and cancer drug resistance, in particular, in the area involving hematopoietic stem cells and leukemia stem cells

Epigenetics, Cancer, Aging and Stem Cells

Dr. Sell is a board certified pathologist and immunologist. He has published over 400 papers and 12 books. His paper with Barry Pierce (Lab. Invest. 70:6-21, 1994.) was selected as an AACR scientific landmark. Among his findings are: development of delayed hypersensitivity before antibody formation (1959). the role of the thymus in development of immune competence (1964); first identification of immunoglobulin on the surface of B cells (1965; Current contents citation classic, 1984); classification of immunopathological reactions (1971); development of a radioimmunoassay for alphafetoprotein (1972); identification of liver stem cells during chemical hepatocarcinogenesis and in response to injury (1972-94); role of endocytosis in activation of B cells (1974); recognition that the chancre of syphilis is a delayed hypersensitivity reaction (1979); role of mGSTA3 in detoxification of aflatoxin (2004); and characterization of breast cancer stem cells (2012)

Cancer: To determine how bone marrow derived mesenchymal stem cells influence the development of cancers in other tissues. Cancer: To block proliferation of breast cancer stem cells by small molecular inhibitors or inhibitory RNA. This is a critical step to preventing re-growth of breast cancer after chemotherapy or radiation therapy. Carcinogenesis: To study the metabolism of aflatoxin and development of liver cancer in mice lacking glutathionine-S-transferase. Aging: To compare the ability of young vs. old bone marrow derived stem cells to reconstitute and provide long term survival after lethal irradiation and transplantation, and the ability of wild-type bone marrow to prolong life of early aging mice.

Bradford has a PhD in Medical Biochemistry- Oncology from the Roswell Park Cancer Institute, Division of SUNY at Buffalo School of Medical and Biomedical Sciences. She is the inventor of the various patents that AccuTheranostics holds. She was awarded the Award for Excellence in Research from the American Federation for Clinical Research, has authored many scientific papers and book chapters, and been an invited speaker at various international scientific meetings. Dr. Bradford is a member of many major professional cancer organizations including, ASCO, AACR and AAAS. As Chief Scientific Officer, Dr. Bradford guides the day-to-day research directives as well as the clinical laboratory operations.

President, CSO and Founder
AccuTheranostics, Inc.,USA

Bishayee is the Chair and Associate Professor of Pharmaceutical Sciences, American University of Health Sciences, Signal Hill, CA. Dr. Bishayee’s research focuses on elucidation of the cancer preventive and therapeutic effects of medicinal plants, natural products, dietary and synthetic agents using various pre-clinical models of cancer. The ongoing projects of Dr. Bishayee are funded by the National Institutes of Health as well as private pharmaceutical/biotechnological institutions. Dr. Bishayee has published more than 86 original research papers and review articles in high-impact, peer-reviewed journals, 9 book chapters, and presented over 25 papers at various national and international scientific meetings.

Assistant Dean and Chair
Associate Professor of Pharmaceutical Sciences
American University of Health Sciences
Signal Hill, USA

Professor Shiaw-Yih Lin has studied DNA damage response in cancer for 10+ years, during which time he has authored more than 40 peer-reviewed reports. He has served on the editorial boards for the World Journal of Clinical Oncology, American Journal of Cancer Research, Frontiers in Molecular and Cellular Oncology, World Journal of Translational Medicine, and Experimental Hematology & Oncology. Dr. Lin is a member of the International Scientific Advisory Board for International Institute of Anticancer Research, and he has served on numerous review committees for the NIH, DOD and Susan G. Komenfor the Cure.

DNA damage checkpoint and DNA repair
Genetic and chemical screens
Cancer stem cells
Cancer gene signatures

Dr. Lu’s work is to delineate the mechanisms of cellular signaling regulation in cancer cell metabolism, proliferation, migration and metastasis. His laboratory focuses on three areas: understanding how cancer advances by altering cancer cell metabolism; understanding how cancer cells migrate, invade and metastasize, and understanding how cancer progresses by promoting cell survival. He is an associate editor of Chinese Journal of Cancer and an editorial board member of other 8 journals including Cell Research and Neuro-Oncology

Tumor cell invasion and metastasis, cancer cell metabolism

Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-); Visiting Professor in Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA (2012–2013); Visiting Professor in Department of Pathobiology, College of Veterinary Medicine, The University of Missouri-Columbia, MO, USA (2012); Visiting Professor in Department of Foods and Nutrition, The University of Georgia, GA, USA (2011 – 2012); Visiting Professor in Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, GA, USA (2007 – 2011); Professor in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1993 ~ August 2007); Associate Professor in Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1991~1993); Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka, Japan (1987~1991); Visiting Assistant Professor in The University of Texas Medical School at Huston, USA (1988); Assistant Professor in Shizuoka College of Pharmacy, Japan (1986~1987); Visiting Assistant Professor in Texas Tech University School of Medicine, USA (1985); Visiting Lecturer in The University of Pennsylvania School of Medicine, USA (1981); Research Associate in Shizuoka College of Pharmacy, Japan (1973 ~ 1986). He received a Ph.D. in Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has completed his B.S. in Pharmaceutical Sciences, Shizuoka, Japan (1971).Dr. Yamaguchi is serving as editors and editorial board members of reputed 24 international Journals. He received many honor and awards.

cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetic osteoporosis, and cancer bone metastasis and osteolysis.

Dr. Salem Chouaib completed his undergraduate studies at the university of Pierre and Marie Curie (Paris VI) at Pasteur Institute. He received his Doctorat es-sciences (Ph.D.) in immunology, (laboratory of Jean Dausset, Nobel prize in medicine) in 1983 from the same university. He then joined the Memorial Sloan Kettering Cancer Center in New York where he undertook a post-doctoral training in Human Immnogenetics Laboratory. In 1986, he was appointed as research associate at the French National Institute of Health and Biomedical Research (INSERM) and joined the tumor biology department at the Institut Gustave Roussy. At present he is research director and is heading the INSERM research unit 753 (Human Cancer Immunology and Immunotherapy). Dr Chouaib’s laboratory currently focuses on the investigation of the functional cross talk between cytotoxic cells and tumor targets in the context of tumor microenvironment complexity and plasticity. Dr Chouaib research was constantly directed at impulsing the transfer of fundamental concepts in clinical application in particular in the field of cancer vaccine and cancer immunotherapy. He was awarded the cancer research prize of the French ligue against cancer in 1992 and in 2004 the presidential prize in biotechnology. He is lecturing tumor immunology for the PhD programs at the University Paris Sud. His research resulted in more than 220 scientific articles and several reviews in the field of human immunology and tumor biology as well as in editorship for contribution to several books. Furthermore he is guest lecturer at different universities. He is ad hoc referee for numerous journals and scientific foundations. He is a member of various professional associations and is scientific advisor and consultant in many scientific institutions.

Cell-mediated cytotoxicity, tumor microenvironment, immunology and immunotherapy of cancer.

Dr. Siddiqui earned his BSc and MSc degrees in Biochemistry from the University of Karachi, in Karachi, Pakistan. He obtained his PhD from the Australian National University in Canberra, Australia. While obtaining his PhD, he investigated the metabolic basis of cancer cachexia under the supervision of Professor John F. Williams, who is famous for his pioneer research on the pentose phosphate pathway. Dr. Siddiqui served as a postdoctoral fellow at Massey University in Palmerton North, New Zealand in the laboratory of Dr. Stuart McCutcheon (currently Vice Chancellor of Auckland University in New Zealand). Dr. Siddiqui immigrated to America in 1989 and worked as a Howard Hughes fellowship at Vanderbilt University Medical Center in Nashville with Dr. John Exton. Dr. Siddiqui began his work as a researcher at Methodist Hospital in 1993 in the Bone Marrow Transplant Research Laboratory. He established his independent research laboratory in 1999 and is presently the Senior Investigator and Director of the Cellular Biochemistry Research Laboratory at the Methodist Research Institute. Dr. Siddiqui also has adjunct appointments in the Department of Biology, Indiana University-Purdue University and the Department of Medicine, Indiana University Medical School, Indianapolis. Dr. Siddiqui has received funding from the National Cancer Center (NIH), American Heart Association, Showalter Foundation, Abbott Pharmaceuticals, and Baxter Nutrition.

Dr. Siddiqui´s research interests are in the area of cancer, inflammation, and cardiovascular diseases. His research emphasis is on the synergistic modulation of breast cancer progression by combination of nutrients and drugs with omega-3 fatty acids.

Professor Ivan Gout graduated as an MD at Lviv Medical University (Ukraine) in 1983. He obtained his doctorate at the Institute of Experimental Oncology, National Academy of Sciences of Ukraine in 1987. In 1998, he started his own group at the Ludwig Institute for Cancer Research, focussing on the regulation of growth via the S6 kinase pathway. Since 2003, he has been a Professor in this Department, where he has an active research group working on signal transduction via the mTOR/S6K pathway in normal and cancer cells.

Cell signalling through phospholipases, kinases and G-proteins during differentiation and secretion, Cellular mechanisms underlying neurodegeneration.

Samir A. Farghaly is Physician / Scientist and national and international expert in Obstetrics and Gynecology – faculty member at the Medical College of Cornell University, and the New York Presbyterian Hospital/ Cornell University Medical Center, New York, NY – USA. He received his M.D degree from University College, London University and his PhD degree in molecular biology from London University. He was affiliated with Columbia University College of Physicians and surgeons/ Columbia University medical center, New York, NY. He received several national and international clinical and research awards. He has been an invited speaker in several national and international conferences on Women’s health, Molecular genetic of female cancers, Gynecological cancer and Oncology. He is a member of several national and international societies, organizations, foundations of Women health and Cancer. He is an editor, member of editorial boards, editorial advisory boards and reviewers of several medical journals of Cancer Science & Therapy, Gynecology, Gynecological Cancer, Genomics, Clinical & Experimental Obstetrics and Gynecology, and Oncology. He has published 78 articles in reputed peer review journals. He has written several books chapters, and is an editor of (2) books in Obstetrics and Gynecology, published in Feb. 2012, and the third book to be published in June 2013.

Obstetrics and Gynecology
Cornell University
USA

Mukesh Verma is Chief of the Epidemiology and Genomics Research Program's (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility. He is responsible for stimulating EGRP-funded research on epigenetic approaches in cancer epidemiology and has been instrumental in developing epigenetics research for NIH as a whole. Dr. Verma helped to develop a Request for Applications (RFA) on Environmental Influences on Epigenetics with the National Institute of Environmental Health Sciences (NIEHS) and represents the Division of Cancer Control and Population Sciences (DCCPS), in NIH's Roadmap Initiative on EpigeneticsExternal Web Site Policy. He helped develop an RFA on Comparative Systems Genetics of Cancer with NCI's Division of Cancer Biology (DCB), and is known within the extramural research community as an EGRP Program Director for Program Announcements (PAs) on Small Grants for Cancer Epidemiology and Pilot Studies in Pancreatic Cancer. He also organized a workshop to explore developing a concept for a research initiative on mitochondrial DNA and cancer epidemiology. Dr. Verma was, and continues to be, a co-Program Director for initiatives in gene-environment interactions in cancer etiology, including the Breast and Prostate Cancer and Hormone-Related Variants Cohort Consortium (BPC3), which is a collaborative project to pool data and biospecimens from a group of large prospective cancer epidemiology cohorts. Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP's former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI's Division of Cancer Prevention (DCP), where he worked in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.

Biomarkers, epigenetics, epidemiology technologies, proteomics, microRNA, methylation, mitochondria, nanotechnology, risk assessment, susceptibility factors, and systems genetics.

Tania Fernandez is the Founder& CEO of Dream Catcher Ventures, a firm with domain expertise in the Biotech and Healthcare sector that renders strategic advisory services to companies in the healthcare /life sciences sector. Having been a scientist, venture capitalist and an entrepreneur, Dr. Fernandez enables and empowers entrepreneurs and investors to create, build and scale businesses effectively through globalization. Dr. Fernandez has over 20 years of in-depth experience in the life sciences and 10 years of venture investing experience in the life sciences/healthcare and healthcare delivery space with Burrill & Company, a $1.5B life science focused fund, having invested right across therapeutics, diagnostics, devices, healthcare and healthcare IT. She secured her doctorate at the Cancer Research Institute, India, having been awarded the Indo-US scholarship from the National Institutes of Health (NIH), USA. Her research work won her the Young Scientist Award and she was also awarded for the most outstanding doctoral thesis. Her postdoctoral work at the National Cancer Institute, National Institutes of Health resulted in two awards for excellence in biomedical research and her research has been published in peer reviewed top tiered scientific journals including Nature Biotech, Journal of Experimental Medicine and Proceedings of the National Academy of Sciences. She also has a post-doctorate from Texas A&M,College of Medicine having specialized in protein chemistry and genetic engineering. Dr. Fernandez speaks at a number of conferences and events both nationally and internationally. She has held Board/Board observer positions on Adlyfe, Strand, White Glove Health and Bioimagene. She also sits on the Advisory Board Member of Express Pharma (Finance), and the editorial Board of “Interdisciplinary Journal of Applied and Biomedical Sciences”. Tania works extensively with entrepreneurs and has been/is involved with mentoring, advising and as an instructor to UCSF, Berkeley, UC Davis, Harvard. She also serves as Principal Advisor to Larta

Protein chemistry, genetic engineering, caging technology and drug delivery systems.

Tamara LahTurnšek has completed her PhD at the age of 32years from University of Ljubljana, did her postdoctoral studies at Wayne State University School of Medicine and.She is the director of National Institute of Biology, leading institute in biology and related disciplines, She is also the Head of national Genetic Toxicology and Cancer Biology Programme and Full Professor at the University of Ljubljana, teaching Tumour Biology at the postgraduate level. She has published about 150 papers in reputed journals and is a recipient of many national and international (EU, ERA net) and inter-regional grants, including the recent Brazil CNPQ grant with the University of Sao Paolo.

Basic research interests of Prof. Tamara Lah Turnšek comprise the role of proteases and their inhibitors in physiological and pathological conditions, in particular in cancer, such as breast and brain tumours, e.g. glioma. Her recent research is focused on the cross–communication between tumour and stromal cells. Among them are the stem cells, originating either from tumours or normal tissue.

Adel Gouri is a Medical laboratory manager at national Institute of Paramedical Education, Algeria. He has published lot of efficient research works and has won awards for his works. His reseach interest lies on Cancer biology and new markers of cancers, Atherosclerosis and lipoproteins metabolism, Hemodialysis and nephrology, Hematologic diseases. He has also presented his papers in many international and national conference.He hold membership over number of Journal boards.

Cancer biology and new markers of cancers, Atherosclerosis and lipoproteins metabolism, Hemodialysis and nephrology, Hematologic diseases

Dr. Xu received her medical degree in 1999 from Weifang Medical College, China. Since then, as a assistant professor she worked at department of immunology, Weifang Medical College. From 2002 to 2007, as a PhD. student, she studied at Peking University Cancer Hospital. Where she mainly focused on the predictive role of p53 gene in breast cancer. In 2007, she obtained her Ph.D. degree at Peking University. From then, she served as an assistant/associate professor at Peking University Cancer Hospital. In March 2015, as a visiting scientist, Dr Xu moved to Mayo Clinic, USA. Dr. Xu mainly focuses on the transnational research of breast cancer.

Her research interesting include (1) the prognostic or predictive markers that sort out the patients who may have a high risk of relapse, or discriminate the patients who may respond to a certain types of neoadjuvant chemotherapy regimens; (2) Germline mutations in BRCA1/2 or other susceptibility genes in Chinese women with early-onset or familial breast cancer.

Dr. Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an MD from the University of Lisbon, Portugal, and a PhD from the University of Uppsala Sweden. He made an internship at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia (USA) and at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France) and was a visiting Professor at the University of Linkoping (Sweden). He published 150 papers in professional Journals and 9 books on cancer and aging. He received the following awards: Fritz Verzar Prize (University of Vienna, Austria), “Seeds of Science”, Career Prize (Lisbon, Portugal), Dr. Honoris Causa (University of Linkoping, Sweden), Johananof International Visiting Professor (Institute Mario Negri, Milano, Italy).

Cancer Research, Cell Biology, Cancer and Aging, Molecular Biology

Liane Deligdisch graduated Medical School in Bucharest, Romania. Following positions were: Gynecologist and General Physician in Romania until 1963, Pathologist at the Ichilov Hospital, Tel Aviv Medical School, Israel 1963 to 1975, Visiting Professor Magee Women Hospital in Pittsburgh, Pa.; 1975-6 Boston Free Hospital for Women, Harvard Medical School ; 1976 to present The Mount Sinai School of Medicine, full Professor of Pathology and Obstetrics-Gynecology and Attending since 1986. Founded the division of Gynecologic Pathology and directed the course of Gynecologic Pathology at the Medical School, Authored 143 peer reviewed articles , 7 textbooks on Gynecologic Pathology.

Gynecology, Obstetrics-Gynecology, Gynecologic Pathology

Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human micro vascular umbilical cord endothelium for lining stents. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the “1st Place - Award for Excellence in Research” from the American Federation for Clinical Research In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemo sensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea on Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer Personalized treatment regimens.Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; commence on July 20 2014; and on the EDITORIAL BOARD of Insights in Cancer Research, and has authored and co-authored a number of scientific peer-reviewed manuscripts.She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA.

Research interest includes human microvascular umbilical cord endothelium and in Pharmacokinetics Oncology

Oliver Micke has completed his PhD at the age of 25 years from Muenster University Hospital in 2006. He is head of the Head of the department for radiotherapy and radiation oncology at the Franziskus Hospital Bielefeld since 2006. In addition he is the medical director of Franziskus Hospital Bielefeld, a premier teaching hospital of the Medical University of Hanover (MHH). He has published more than 200 papers in reputed national and international journals and has been serving as reviewer as well as an editorial board member of repute.

Radiotherapy, Radiation Oncology

ORONZO BRUNETTI graduated cum laude in 2008 from the University of Bari School of Medicine, Bari, Italy. Since graduation, he has become involved in studies on translational research in solid tumors. Since 2014, he is a member of AIOM (the Italian Association of Medical Oncology). Since 2015, he is a member of the Italian Group for Diagnosis and Treatment of Biliary Cancer (GICO). From 2016 he has been involved in the elaboration of guidelines of exocrine pancreatic carcinoma for the AIOM.

Identification of prognostic/predictive biomarkers in pancreatic, biliary, and hepatocellular cancer.

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.

Cancer research, Charged particle optics and Early detection of cancer and delayed detection of cancer.

Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed non-invasive quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.

Acupunture & Electro-Therapeutics Research, Integrative Oncology

Homer S. Black is a Professor of Dermatology, Baylor College of Medicine, Houston, Texas (1968- 2003).He is a Research Physiologist and Director of the Photobiology Laboratory at the Veterans Affairs Medical Center in Houston. Dr. Black earned a Ph.D. in biochemistry from Louisiana State University in 1964. He earned a B.Sc. in animal science from Texas A&M University in 1956 after which he served with the U.S. Air Force in Strategic Air Command and holds a M.Ed. from Sam Houston State University; and a M.S.Admin. (business/health science management) from the University of Houston. He was a Senior Fulbright Scholar at the Photobiology Centre, University of Dundee, Scotland. . He served as Treasurer in the latter. Dr. Black is also a member of the Institute of Professional Managers and was Chairman of the Board of Regents for the Academy of Administrative Managers.

Pro-carcinogenic effects of antioxidants and dietary fat in UV-carcinogenesis. The experimental studies culminated in a dietary intervention trial in which it was shown that a low-fat dietary intervention reduced the risk for subsequent skin cancers in skin cancer patients.

The central theme of Gary Stein’s research has been to discover mechanisms controlling proliferation and differentiation emphasizing compromised regulation linked with disease. His lab characterizes transcriptional regulation that mediates cell cycle control, focusing on molecular mechanisms regulating gene expression at the G1/S phase transition in normal and tumor cells and the abbreviated pluripotent cell cycle in human embryonic stem cells. He has a major commitment to investigating bone tissue specific gene expression, including microRNA-mediated control, within the context of skeletal development and bone remodeling as well as aberrations that accompany the onset and progression of skeletal disease. The Stein lab is defining functional relationships between the subnuclear organization of regulatory proteins and gene expression, pursuing mechanisms that support combinatorial organization and assembly of regulatory machinery in nuclear microenvironments and epigenetic control of cell fate and lineage commitment in biological control and cancer.

Cell proliferation, differentiation, cell cycle control

Dr. Phillips is a national leader in the treatment of hematologic malignancies and is an innovator in bringing transplant modalities to lymphoma. He is a graduate of the University of Oklahoma School of Medicine where he completed his internship in internal medicine. He continued his residency training at the University of North Carlina School of Medicine and trained at Washington University School of Medicine with a clinical and research fellowship in hematology/oncology. He previously directed the transplant programs at the University of Maryland, University of Kentucky, theUniversity of British Columbia, and Barnes Hospital at the Washington University School of Medicine. Dr. Phillips was the principal investigator of the National Cancer Institute (NCI) study "Improving the Ability of (High-Risk) Hematologic Malignancy Patients to Undergo Allogenic Stem Cell Transplantation".

Hematologic malignancies, Allogenic Stem Cell Transplantation,Internal medicine,Lymphoma.

Mitchell Ho is an Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute (NCI). Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NCI working on immunotoxin therapy of cancer. Research in Dr. Ho’s laboratory studies mesothelin, CA125/MUC16 and other cell adhesion molecules as therapeutic targets in order to develop novel antibodies and immunoconjugates to treat ovarian cancer, mesothelioma and liver cancer. He has developed the mammalian cell display method which is currently being used by investigators worldwide to identify and engineer therapeutic antibodies. Dr. Ho is a recipient of Mesothelioma Applied Research Foundation Award, and Ovarian Cancer Research Fund Individual Investigator Award.

Ovarian cancer, liver cancer.

Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-); Visiting Professor in Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA (2012–2013); Visiting Professor in Department of Pathobiology, College of Veterinary Medicine, The University of Missouri-Columbia, MO, USA (2012); Visiting Professor in Department of Foods and Nutrition, The University of Georgia, GA, USA (2011 – 2012); Visiting Professor in Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, GA, USA (2007 – 2011); Professor in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1993 ~ August 2007); Associate Professor in Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1991~1993); Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka, Japan (1987~1991); Visiting Assistant Professor in The University of Texas Medical School at Huston, USA (1988); Assistant Professor in Shizuoka College of Pharmacy, Japan (1986~1987); Visiting Assistant Professor in Texas Tech University School of Medicine, USA (1985); Visiting Lecturer in The University of Pennsylvania School of Medicine, USA (1981); Research Associate in Shizuoka College of Pharmacy, Japan (1973 ~ 1986). He received a Ph.D. in Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has completed his B.S. in Pharmaceutical Sciences, Shizuoka, Japan (1971). Dr. Yamaguchi is engaged in the fields of bone and calcium endocrinology and cell calcium signaling since 1971, and these researches are developed in the aspect of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology, and toxicology. Dr. Yamaguchi has an interesting for cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetic osteoporosis, and cancer bone metastasis and osteolysis. Moreover, Dr. Yamaguchi discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978) and transcriptional factor RGPR-p117 (regucalcin gene promoter region-related protein; 2001) in mammalian cells. Dr. Yamaguchi generated regucalcin transgenic rats, which were registered as international patents (USA, EU, Japan, and Korea), and this animal is found to induce osteoporosis and hyperlipidemia. Recently, Dr. Yamaguchi proposes that regucalcin is a target molecule in carcinogenesis of various cancer cell types. Currently, the research of regucalcin is focused as a scientific topic. Dr. Yamaguchi published over 500 English articles to professional journals with peer-review. In addition, Dr. Yamaguchi registered over 20 national and international patents in the fields of his research interesting. Dr. Yamaguchi is serving as editors and editorial board members of reputed 40 international Journals. He received many honor and awards; Prize for Sato Memorial Fundation (1992, Japan/USA), Senji Miyata Foundation Award 2005 (Japan), Japan Society for Biomedical Research on Trace Elements Award 2007, The Lifetime Achievement Award from International Biographical Centre (IBC) (2004, England), The World Lifetime Achievement Award from American Biographical Institute (2004, USA), The Distinguished Service to Science Award from IBC (2007, England), and many others. Dr. Yamaguchi is listed in various biographies; Who’s Who in the World (2005-, Marquis Who’s Who, USA), Who’s Who in Sciences and Engineering (2004-, Marquis Who’s Who, USA), International Biographical Dictionary (2006-, IBC, England), and others.

Cancer and Oncology, Toxicology, Pharmacology

Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee, and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.

Biochemistry, Molecular Biology, Radiation Biology, Molecular Carcinogenesis and Tumor Biology.

Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee, and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.

Biochemistry, Molecular Biology, Radiation Biology, Molecular Carcinogenesis and Tumor Biology.

Chulso Moon is having 1. Tenure Track Professorship in the Department of Oncology, Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine (2001-2007). 2. Principal Investigator, The Head and Neck Cancer Research Institute, The Johns Hopkins University School of Medicine (Director: Dr. David Sidransky) (2001-). 3. Attending physician, The Johns Hopkins Hospital (2001-2006). 4. Principal investigator, ONXY-015 cancer genetherapy program for advanced head/neck cancer (2001-2003). 5. Adjunct Professorship, Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University school of Medicine (2008- Present). 6. Preceptor, Graduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University school of Medicine (2005- Present, Thesis Advisor for Juna Lee, 2010 Ph.D. Candidate). 7. Director of Medical Oncology, Cleo Craig Memorial Cancer Clinic, The South-Western Medical Center, Lawton OK (2010-Present).

Cancer gene therapy.

Mong-Hong Lee is currently Professor in the Department of Molecular and Cellular Oncology of University of Texas MD Anderson Cancer Center and a faculty member at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS). In 1993, Dr. Lee received his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh, where he received the Stanton C. Crawford Award for teaching excellence. He then went on to complete a postdoctoral fellowship while serving as a research associate at Howard Hughes Medical Institute and Memorial Sloan-Kettering Cancer Center (1993-1997). After completing his fellowship, Dr. Lee came to M. D. Anderson in 1997 as an Assistant Professor (tenure track). He was promoted to his current position of Professor (tenured) in 2010. During his time at M. D. Anderson, Dr. Lee has been the principal investigator or a co-principal investigator for nine funded research projects. He also has been a grant reviewer for several funding agencies. Dr. Lee has been honored for his research activities, led by the Susan G. Komen Breast Cancer Foundation Research Award (2001), Fleming and Davenport Research Award (2001), and William G. McGowan Foundation Research Award (1998). In addition to research, for more than a decade, Dr. Lee has been a key contributor to the education of trainees at M. D. Anderson and the GSBS in a variety of ways. For example, at the GSBS, he has been the course coordinator for the Molecular Genetics of Human Cancer seminar since 2006 and an instructor for the Cancer Cell Signaling course since 2000. Dr. Lee has had a wealth of direct interaction with trainees throughout his career. Specifically, he has directly supervised 40 graduate students, 12 clinical residents and fellows, 12 undergraduate and Allied Health students, 9 postdoctoral research fellows, and 1 medical student. Furthermore, he has chaired or served on 71 examining committees, 67 advisory committees, and 39 supervisory committees. UT M. D. Anderson Cancer Center and the UT GSBS at Houston have well recognized Dr. Lee’s educational efforts. In 2009, he received the John P. McGovern Outstanding Teaching Award, which is given annually to a faculty member at M. D. Anderson and/or the GSBS. Most recently, he has recently been named the February 2010 Faculty Educator of the Month at MD Anderson Cancer Center. Also, he received the M. D. Anderson Outstanding Educator Award in 2003. Currently, Dr. Lee is an ad hoc reviewer for 25 journals. He also has been a guest editor for the journal Breast Diseases. Over the course of his career, Dr. Lee has authored more than 50 articles published in peer-reviewed journals, 4 book chapters, and 3 invited articles.

Characterizing the roles of Cdk inhibitors (CKIs) in cancer formation, and exploiting signaling regulation in cancer therapy. Research projects focusing on: 1) roles of two CKI molecules that he cloned in tumorigenesis; 2) COP9 signalosome signaling regulation; 3) investigating the impact of hypoxia and PIm1 kinase in drug resistance; 4) employing Aurora B kinase inhibitor for cancer therapy; 5) p53-MDM2 signaling regulation and DNA damage; 6) Myc ubiquitination regulation; 7) Glycolysis and cancer metabolism.

Dr. Jimmy Efird is an Associate Member of the Leo Jenkins Cancer at Brody School of Medicine. Additionally, he holds a joint appointment as Associate Professor in the Department of Public Health and as Epidemiologist/Chief Statistician (Director, Shared Resources) in the Center for Health Disparities. Dr. Efird received his Ph.D. from Stanford University (Epidemiology with a concentration in Biostatistics). His expertise includes statistical methods for assessing gene-environment interaction, clinical trial design, computing power and sample size for correlated samples, and multiplicity adjustment for confidence intervals. He has over 100 publications in scientific journals and technical proceedings. Additionally, Dr. Efird serves as a Senior Consultant for The NCRR-funded RCMI Translational Research Network Data and Technology Coordinating Center.

Genetic epidemiology, cancer informatics, brain tumors, soft-tissue sarcomas, and HPV-related cancers. Additionally, he is founding co-chair for the advances in Bioinformatics and Genomics Symposium series. Dr. Efird has over 100 publications in scientific journals and proceedings.

Dr. Uqbah Iqbal is a Socioeconomic Researcher at Research for Social Advancement. Winning Second Place in Malaysian Historical Essay Writing Competition 2013, he was the recipient of Research University Fellowship Scheme, Graduate on Time Award and Outstanding Student Award from Faculty of Social Sciences and Humanities as well as the Youngest Ph.D. in History Holder and the only Malaysian achieved a Ph.D. in History in conjunction with the 43rd Convocation of Universiti Kebangsaan Malaysia. He's authoring notable books/ebooks such as The Historical Development of the Malay Nationalism Before Independence, The Historical Development of the Malay Society Economic Nature During Pre-Colonial Era, The Historical Development of British Investment in Malaya Before the Second World War, The Historical Development of Foreign Investment in the Formation of the Malaysian Economy and Sejarah Pemikiran Pandang Ke Timur: Kepentingan Jepun Dalam Pembangunan Sosio-Ekonomi Malaysia (1906-1980). His publications have appeared in a wide range of international and national journals such as TAWARIKH, SUSURGALUR, Management and Administrative Sciences Review, Social and Basic Sciences Research Review, Jurnal Kemanusiaan, Jurnal Sejarah, Jurnal Pengajian Melayu, Jebat, International Journal of Social Science and Humanities Research, Asia Pacific Journal of Education, Arts and Sciences, Asian Social Science and Geografia. He's also actively in the editorial board such as Asian Social Science, International Journal of Art and Literature, International Journal of Archaeology and History, American Journal of Social Sciences, Asia Pacific Journal of Education, Arts and Sciences, Social Sciences, Humanities and Social Sciences, History Research and Pratidhwani the Echo. Through his involvement as a reviewer with the Nonfiction Authors Association, 15 of his reviewed books received Awards.

Research for Social Advancement.

Giulio Tarro, graduated from Medicine School of Naples University. Research Associate at Division of Virology and Cancer Research, Children’s Hospital and Assistant Professor of Research Pediatrics, College of Medicine, Cincinnati, Ohio. He is a Professor of Oncological Virology at University of Naples. He worked for National Research Council, Rome, and for National Cancer Institute, Frederick Center, Maryland. He became Division Chief of Virology, and then Department Chief of Diagnostic Laboratories, D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006-. Since 2007 he is Chairman Committee on Biotechnologies and Virus Sphere World Academy Biomedical Technologies, UNESCO, and Adjunct Professor Department Biology Temple University College of Science and Techology, Philadelphia. Recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumor antigens, which were the “finger-prints” left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas. President Foundation de Beaumont Bonelli for Cancer Research.

Foundation T. & L de Beaumont Bonelli for cancer research

Dr Manzoor is presently working as Head Department of Bioresources, School of Biological Sciences, University of Kashmir Srinagar India. He has been awarded Summer Research Fellowship by Indian National Science Academies for year 2019 and Teacher Associate for Research Excellence award by the Science and Engineering Research Board Ministry of DST Govt. of India in 2018. Dr Manzoor Ahmad Mir did his master’s in Life Sciences with Gold Medal and after qualifying CSIR-JRF-NET, he joined Ph. D in Immunology at Jawaharlal Nehru University. He started his teaching and Research career in 2009 as Assistant Professor and joined University of Kashmir in the year 2012. He worked as Research Scientist at Majmaah University Saudi Arabia in SATCAS Stroke Research Chair from 2013 to 2015. Dr Manzoor has an outstanding research experience of 16 years which is evident from the research publications. He has published 13 international Books with Thompson Reuters Web of Science publishers like Elsevier USA, Academic Press USA, NOVA Biomedical Sciences USA and OMICS international UK. He has more than 50 book chapters to his credit with the publishers of international repute besides having published more than 40 Research papers in reputed peer reviewed international Journals like PLOS pathogen, Frontiers in Neurosciences, Expert Opinion in Therapeutic Targets, Current Cancer Drug Targets, Cancer Chemotherapy and Pharmacology, Current Pharmaceutical Biotechnology, Current Immunology Reviews etc. He has guided more than 20 master’s students for their thesis and is guiding eight Ph D Research Scholars. He has developed more than 50 online MOOC module lectures for masters and Bachelors students. He was selected as MOOC Course Coordinator for Immunology in 2018 and Endocrinology in 2019 by the Academic advisory committee of CEC-UGC-MHRD Govt of India. Dr. Manzoor has attended many courses and conferences on immunology, cancer Biology, stroke biology and Infectious Diseases at USA, UK, Kuwait, China, UAE, Scotland and Saudi Arabia. His basic research interests include Cancer Immunology, Tuberculosis immunobiology and Stroke Biology. He is currently working on Combinational therapies in Tripple negative breast cancer. Dr. Manzoor is on the editorial board of some prestigious journals and has been an invited speaker at various scientific meetings/conferences within India and abroad. He is member of many scientific organizations and societies like International Immunology Association, Indian Association of Immunology, CHASCON, Indian National Science Association, IMMUNOCON etc.

In Neurosciences, Therapeutic Targets, Current Cancer Drug Targets, Cancer Chemotherapy and Pharmacology, Current Pharmaceutical Biotechnology, Current Immunology